Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Growth/Differentiation Factor 8 (Myostatin or GDF-8) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Growth/Differentiation Factor 8 (Myostatin or GDF-8) Products under Development by Stage of Development | 8 | 1 |
| Growth/Differentiation Factor 8 (Myostatin or GDF-8) Products under Development by Therapy Area | 9 | 1 |
| Growth/Differentiation Factor 8 (Myostatin or GDF-8) Products under Development by Indication | 10 | 1 |
| Growth/Differentiation Factor 8 (Myostatin or GDF-8) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Growth/Differentiation Factor 8 (Myostatin or GDF-8) Products under Development by Companies | 13 | 2 |
| Growth/Differentiation Factor 8 (Myostatin or GDF-8) Therapeutics Assessment | 15 | 6 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 2 |
| Growth/Differentiation Factor 8 (Myostatin or GDF-8) Companies Involved in Therapeutics Development | 21 | 9 |
| Acceleron Pharma, Inc. | 21 | 1 |
| Atara Biotherapeutics, Inc. | 22 | 1 |
| Bristol-Myers Squibb Company | 23 | 1 |
| Eli Lilly and Company | 24 | 1 |
| Milo Biotechnology LLC | 25 | 1 |
| Pfizer Inc. | 26 | 1 |
| Regeneron Pharmaceuticals, Inc. | 27 | 1 |
| Sarepta Therapeutics, Inc. | 28 | 1 |
| Scholar Rock, Inc. | 29 | 1 |
| Growth/Differentiation Factor 8 (Myostatin or GDF-8) Drug Profiles | 30 | 22 |
| AAV1-Foliistatin Drug Profile | 30 | 2 |
| AAV9-Follistatin Drug Profile | 32 | 1 |
| ACE-083 Drug Profile | 33 | 2 |
| ACE-2494 Drug Profile | 35 | 1 |
| ACE-2798 Drug Profile | 36 | 1 |
| Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD Drug Profile | 37 | 1 |
| ATA-842 Drug Profile | 38 | 1 |
| BMS-986089 Drug Profile | 39 | 1 |
| domagrozumab Drug Profile | 40 | 2 |
| landogrozumab Drug Profile | 42 | 1 |
| luspatercept Drug Profile | 43 | 6 |
| OSX-200 Drug Profile | 49 | 1 |
| SRK-015 Drug Profile | 50 | 1 |
| trevogrumab Drug Profile | 51 | 1 |
| Growth/Differentiation Factor 8 (Myostatin or GDF-8) Dormant Projects | 52 | 1 |
| Growth/Differentiation Factor 8 (Myostatin or GDF-8) Discontinued Products | 53 | 1 |
| Growth/Differentiation Factor 8 (Myostatin or GDF-8) Featured News &Press Releases | 54 | 12 |
| May 19, 2016: Acceleron Announces Data Presentations with Luspatercept at the 21st Congress of the European Hematology Association | 54 | 1 |
| May 09, 2016: Follistatin Gene Therapy Increases Function in Inclusion Body Myositis Patients | 55 | 1 |
| Dec 07, 2015: FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Lower-Risk Myelodysplastic Syndromes | 55 | 1 |
| Dec 05, 2015: Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Myelodysplastic Syndromes Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition | 56 | 1 |
| Dec 01, 2015: Acceleron Announces Oral Plenary Presentation for ACE-083 in the Late Breaking Clinical Trials Session at the 8th International Conference on Cachexia, Sarcopenia and Muscle Wasting | 57 | 1 |
| Nov 05, 2015: Acceleron Announces New Data on Luspatercept at the 2015 American Society of Hematology Annual Meeting | 57 | 1 |
| Oct 23, 2015: Acceleron Highlights Phase 3 Studies, New Clinical Results and Research Strategies at Research and Development Day Event | 58 | 1 |
| Oct 01, 2015: Acceleron Presents Preclinical Data for ACE-083 at the 20th International Annual Congress of the World Muscle Society | 59 | 1 |
| Oct 01, 2015: Acceleron Presents Preclinical Data for ACE-2494 at the 20th International Annual Congress of the World Muscle Society | 60 | 1 |
| Sep 23, 2015: Scholar Rock Presents First Data for Niche Modulator Inhibiting Myostatin Activation and Announces SRK-015 as Lead Drug Program | 60 | 1 |
| Jun 12, 2015: Acceleron Announces New Luspatercept Phase 2 Clinical Results at the 20th Congress of the European Hematology Association | 61 | 1 |
| Jun 09, 2015: Acceleron Pharma to Host Conference Call and Webcast to Review New Luspatercept Data Presented at the 20th Congress of the European Hematology Association | 62 | 1 |
| May 21, 2015: Acceleron to Present Luspatercept Clinical Trials at the 20th Congress of the European Hematology Association | 63 | 1 |
| May 18, 2015: FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia | 63 | 1 |
| May 02, 2015: Luspatercept Data Presented at the 13th International Symposium on Myelodysplastic Syndromes | 64 | 2 |
| Appendix | 66 | 2 |
| Methodology | 66 | 1 |
| Coverage | 66 | 1 |
| Secondary Research | 66 | 1 |
| Primary Research | 66 | 1 |
| Expert Panel Validation | 66 | 1 |
| Contact Us | 66 | 1 |
| Disclaimer | 67 | 1 |